With our Telehealth services, DISC is ready to take care of you.      Learn More »

Chemonucleolysis Requires Chymopapain: Should We Accept Its Unavailability?

  • Version
  • Download 23
  • File Size 448.51 KB
  • Create Date March 25, 2008

The production of chymopapain and its availability in the United States and Europe has been discontinued by its manufacturer. This creates an untenable and unacceptable situation. Our patients are without chemonucleolysis (CNL), a proven treatment for disc related nerve root pain. FDA confirmed that Chymodiactin®, which is injected during the CNL procedure, was not discontinued for reasons of safety or effectiveness

LEADERS IN MINIMALLY INVASIVE SPINE CARE
Copyright © 1996-2020 Desert Institute for Spine Care
1635 E. Myrtle • Suite 400 • Phoenix, AZ 85020
Ph: 602-944-2900 • Fax: 602-944-0064